<DOC>
	<DOCNO>NCT02504268</DOCNO>
	<brief_summary>The purpose study determine abatacept effective treatment early rheumatoid arthritis .</brief_summary>
	<brief_title>Effects Abatacept Patients With Early Rheumatoid Arthritis</brief_title>
	<detailed_description>Subcutaneous ( SC )</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Rheumatoid arthritis ( RA ) diagnosis le 6 month CRP &gt; 3 mg/L Erythrocyte Sedimentation Rate ( ESR ) â‰¥ 28 mm/h At least 3 swollen 3 tender joint Anticitrullinated protein antibody ( ACPA ) positive At risk tuberculosis Have acute infection Have chronic recurrent bacterial serious latent viral infection History malignancy last 5 year except squamous skin , basal skin cervical carcinoma Previous treatment conventional biologic Diseasemodifying anti rheumatic drug ( DMARD )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>